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about 10 % of the mutations detectable by whole exome 
sequencing (WES) were missed (Saudi Mendeliome Group 
2015). In fact, gene panels related to the patients’ pheno-
type can be viewed as an inexpensive and rapid first-tier 
test. If this test is negative, WES or whole genome sequenc-
ing (WGS) can be considered as the most comprehensive 
second-tier test.
In WGS, genome-wide read coverage may allow reli-
able detection of copy number variations (CNVs), which 
can contribute substantially to disease burden (Girirajan 
et al. 2011). The prices of WGS are tumbling, turnaround 
time including data analysis (e.g., using GENALICE MAP, 
www.genalice.com) can be reduced to few days, virtual 
gene panels can be selected in silico to avoid inciden-
tal findings, and diagnostic yield may be as high as 73 %, 
surmounting conventional phenotype-directed single-gene 
analyses by up to one order of magnitude (Soden et al. 
2014; Miller et al. 2015; Willig et al. 2015). Thus, WGS 
has to be considered as an alternative to WES.
We recently showed that even current WES platforms 
have problems in sufficiently capturing the whole exome 
and suggested that WGS, which forgoes capturing, is less 
sensitive to GC content and more likely than WES to pro-
vide complete coverage of the entire coding region of the 
genome (Meienberg et al. 2015). Here, we provide new 
insights into WGS, showing that the recently introduced 
PCR-free WGS offers hitherto unprecedented complete 
coverage of the coding region of the genome and, hence, 
that WGS instead of WES should be considered as the most 
comprehensive second-tier test.
We compared optimal WES (using Agilent SureSelect 
v5 + UTR capturing; Meienberg et al. 2015) with WGS 
(using Illumina’s TruSeq PCR-free WGS library prepa-
ration) in DNA samples of five females each. Sequenc-
ing was performed by vendors V2 (WES) and V4 (WGS) 
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on a HiSeq 2000 at 100× and a HiSeq X Ten system at 
60×, respectively. To largely reduce systematic errors and 
alignment artifacts, we restricted our comparison to Ref-
Seq coding sequences which were uniquely mappable to 
X-chromosomal or autosomal regions (Derrien et al. 2012), 
identical in hg19 and hg38 genome assemblies, and not 
overlapping with common CNVs listed in the Database of 
Genomic Variants (DGV, MacDonald et al. 2014). For fur-
ther details see electronic supplementary material.
Our current data show that novel PCR-free WGS is much 
less sensitive to GC content and leads to a more uniform 
coverage than WES and non-PCR-free WGS (Fig. 1a, Sup-
plementary Figs. S1-S3). Although the average depth of 
coverage was less than half (65× in WGS versus 154× in 
WES, Supplementary Table S1), the number of RefSeq cod-
ing exons with complete (100 %) coverage at ≥13× was 
considerably larger in PCR-free WGS than in WES (100.00 
vs. 98.15 %; Fig. 1b). The difference was more pronounced 
when the GC-rich first exons (59 vs. 51 % GC in all exons) 
were examined (100.00 % in PCR-free WGS vs. 93.60 % 
in WES; Fig. 1b). In the case of genes recommended by 
the American College of Medical Genetics (ACMG) to 
be reported if mutated (Green et al. 2013), PCR-free WGS 
completely covered all uniquely mappable exons (100 % 
at ≥13×) in all five samples of our study, whereas only 
98.25 % of the ACMG exons were completely covered by 
WES, leading to complete WES coverage of only 75.56 % 
of the ACMG genes (Fig. 1b). A noticeable and clini-
cally relevant difference in the performances of WES and 
WGS was also observed in the coverage of exons in which 
disease-causing mutations (DMs, including single nucleo-
tide variants as well as small (≤20 bp) insertions, deletions, 
and indels) have been reported in HGMD (98.22 % in WES 
vs. 100.00 % in WGS; Fig. 1b). Accordingly, WES may 
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Fig. 1  Performance comparison of WES and WGS. a Mean read 
depth of RefSeq coding exons per GC content shown for WES as 
well as for WGS with (WGS_wPCR) and without (WGS) PCR as 
means of five samples each. b Percentage of completely covered 
(i.e. ≥13 reads at each nucleotide position) genes, exons, and variants 
in WES and WGS without PCR as means of five samples each (error 
bars indicate 95 % confidence intervals). In the case of genes recom-
mended for reporting by the ACMG (ACMG genes, n = 54) and of 
genes of the RefSeq database (RefSeq genes, n = 16,896), the set 
of all coding exons (ACMG all exons, n = 1152; RefSeq all exons, 
n = 177,084) and the set of start-codon-containing exons (first exons) 
were examined. The set of RefSeq exons harboring at least one dis-
ease-causing mutation (DM) listed in HGMD (HGMD all exons, 
n = 22,303) and the set of all coding and non-coding DMs (HGMD 
all variants, n = 106,819) were also analyzed. Note that 100.00 % 
implies a deviation of at most 0.005 %: *two exons were partially 
covered with 12 reads; #one intronic mutation was covered with 12 
reads; &12 genes were partially covered with 7–12 reads; ¶three exons 
were partially covered with 10–12 reads; §12 exons were partially 
covered with 7–12 reads
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fail to detect 0.42 % (401/95,118) of the currently known 
exonic DMs detectable by WGS. Considering the identifi-
cation of non-coding pathogenic variation as well (Spiel-
mann and Klopocki 2013), WES may miss a total of 0.81 % 
(863/106,819) of the DMs currently listed in HGMD and 
potentially detectable by WGS (99.19 % in WES vs. all but 
one DM in WGS; Fig. 1b). Notably, the 13× cutoff presented 
here reveals the minimum number of reads at which WGS 
achieves 100.00 % coverage in our samples. For the same 
WGS performance at the widely used 20× cutoff, sequenc-
ing at >100× (65 ∗ 20/13) is needed (while for WES more 
sequencing reads may not result in more complete coverage 
due to capture limitations, especially in GC-rich regions).
Furthermore, genome-wide uniformity of coverage 
makes WGS, rather than WES, suitable for CNV detection 
(Gilissen et al. 2014; Meienberg et al. 2015). In our sam-
ples, the coefficient of variation (cv = SD/mean) in cover-
age among the exons of an individual is on average about 4 
times larger in WES than in PCR-free WGS (0.59 vs. 0.14). 
Admittedly, the relative lack of uniform coverage in WES 
does not appear to result from an increased noise level, 
since the inter-individual cv per exon is comparable in WES 
and WGS (0.08 vs. 0.09). In other words, the additional 
variability of WES coverage appears to be reproducible and, 
hence, can in principle be normalized in silico. However, 
such normalization algorithms are relatively complex, need 
to be calibrated for each enrichment protocol (Szatkiewicz 
et al. 2013), and allow only the detection of CNVs affect-
ing the enriched genomic region. Moreover, gapless WGS 
also offers the detection of structural variants (SVs) based 
on paired and split reads, enabling the detection of (copy 
neutral) SVs at base-pair resolution (Escaramis et al. 2015). 
Thus, in our opinion, WGS will likely replace array tech-
niques in CNV detection whereas WES might not.
WGS is available worldwide in laboratories that 
have high-throughput sequencing capacities of at least 
60× 3 ∗ 109 bp as well as appropriate hard- and software 
resources to handle and interpret large WGS files. One may 
argue that WGS is more expensive than NGS with selective 
capturing of targets. Indeed, genetic mosaics and somatic 
cancer gene panels require several 100-fold sequencing 
depths to detect low-frequency non-reference variants, so 
that WGS would currently be too expensive for these appli-
cations. Otherwise, however, sequencing costs decline stead-
ily and data interpretation efforts can be curtailed by in silico 
selection of relevant WGS parts. Considering that these parts 
are subject to change, selective capturing will require re-
sequencing of unsolved cases, while with WGS only the re-
analysis of existing data will be necessary. In addition, one 
may argue that WGS implies incidental findings of muta-
tions not related to the patient’s present disease and findings 
of variants with uncertain or incomplete effect. Again, over-
load with such findings can be prevented by reducing the 
WGS data to virtual gene panels of interest. Thus, we and 
others (Belkadi et al. 2015; Lelieveld et al. 2015) believe that 
WGS is more powerful than WES in detecting exome vari-
ants so that future NGS diagnostics of Mendelian disorders 
will not involve capturing techniques anymore. In addition to 
previous studies, our present data show that PCR-free WGS 
provides an even more uniform and complete coverage of 
the exome than WGS with PCR during library preparation.
In conclusion, the performance of WES is sensitive to 
sequence (GC) content as well as capturing design and 
enrichment. Hence, WES does not entirely serve its pur-
pose, whereas novel PCR-free WGS provides hitherto 
unprecedented complete coverage of the exome and other 
clinically relevant genomic sequences. The advantage of 
WGS therefore does not only include the identification of 
non-coding pathogenic variation, but, in view of its more 
complete exomic coverage as presented here, it is simply 
the better WES. As such, PCR-free WGS has to be con-
sidered as the most comprehensive second-tier genomic 
test. With sequencing costs further declining and by using 
appropriate virtual panels, WGS even has the potential to 
entirely replace WES and other techniques that involve 
selective capturing of target sequences.
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